A super-agonist of growth hormone–releasing hormone causes rapid improvement of nutritional status in patients with chronic kidney disease  by Niemczyk, Stanisław et al.
see commentary on page 385
A super-agonist of growth hormone–releasing
hormone causes rapid improvement of nutritional
status in patients with chronic kidney disease
Stanisław Niemczyk1, Hanna Sikorska2, Andrzej Wie˛cek3, Ewa Z˙ukowska-Szczechowska4, Klaudia Załe˛cka5,
Joanna Gorczyn´ska5, Małgorzata Kubik3, Beata Czerwien´ska3, Katarzyna Gosek4, Johannes D. Veldhuis6,
David A. Wagner7, Pierrette Gaudreau8, Tiina Hakonen9, Sam Wai Kit Kay2, Taneli Jouhikainen2 and
Franz Schaefer10
1Department and Clinic of Nephrology, Dialysis, and Internal Medicine, Warsaw University of Medicine, Banacha Hospital, Warsaw,
Poland; 2Akela Pharma Inc., Saint-Laurent, Que´bec, Canada; 3Clinic of Nephrology, Endocrinology and Metabolic Diseases of Mielecki
Hospital, Silesian University of Medicine, Katowice, Poland; 4Clinic of Internal Medicine, Diabetes and Nephrology of Stanisław Szyszko
Hospital, Silesian University of Medicine, Katowice, Poland; 5Division of Internal Medicine with Dialysis Station, Public Hospital,
Wołomin, Poland; 6Division of Endocrinology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA; 7Metabolic Solutions Inc.,
Nashua, New Hampshire, USA; 8Centre Hospitalier de l’Universite´ de Montre´al Research Center and Department of Medicine, University
of Montreal, Que´bec, Canada; 9Encorium Oy, Espoo, Finland and 10Division of Pediatric Nephrology, Heidelberg University Medical
Center, Heidelberg Germany
Chronic kidney disease is frequently associated with
protein-energy wasting related to chronic inflammation
and a resistance to anabolic hormones such as insulin
and growth hormone (GH). In this study, we determined
whether a new GH-releasing hormone super-agonist
(AKL-0707) improved the anabolism and nutritional status
of nondialyzed patients with stage 4–5 chronic kidney disease
randomized to twice daily injections of the super-agonist or
placebo. After 28 days, this treatment significantly increased
24-h GH secretion by almost 400%, without altering the
frequency or rhythmicity of secretory bursts or fractional
pulsatile GH release, and doubled the serum insulin-like
growth factor-1 level. There was a significant change in
the Subjective Global Assessment from ‘mildly to moderately
malnourished’ to ‘well-nourished’ in 6 of 9 patients receiving
AKL-0707 but in none of 10 placebo-treated patients.
By dual-energy X-ray absorptiometry, both the mean fat-free
mass and the body mineral content increased, but fat mass
decreased, all significantly. In the AKL-0707-treated group,
both serum urea and normalized protein equivalent of
nitrogen appearance significantly decreased with no change
in dietary protein intake, indicating a protein anabolic effect
of treatment. Thus, our study shows that stimulation of
endogenous GH secretion by AKL-0707 overcomes uremic
catabolism of patients with advanced chronic kidney disease.
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Chronic kidney disease (CKD) is frequently associated with
protein-energy wasting related to chronic inflammation and
resistance to the actions of anabolic hormones, such as
insulin and growth hormone (GH).1 The resulting complex
of malnutrition, inflammation, and accelerated atherosclero-
sis (known as the MIA syndrome) is a major cause of
excessive morbidity and mortality observed in these patients.2
Molecular mechanisms of uremic GH resistance include
impaired postreceptor signaling,3 reduced bioavailability of the
downstream mediator insulin-like growth factor-1 (IGF-1) due
to increased plasma protein binding,4,5 and possibly impaired
IGF-1 target tissue signaling.6 Resistance to endogenous GH
can be partially overcome by administration of recombinant
human GH (rhGH) at pharmacological doses.7–12 rhGH is an
approved treatment of growth failure in children with CKD
and causes anabolic effects7–11 and an improved quality of
life11,12 in adults undergoing dialysis,7–11 but clinical experience
in adults with pre-dialytic CKD is lacking.
Spontaneous pulsatile GH secretion is mainly regulated
by the interplay of two hypothalamic hormones, namely
GH-releasing hormone (GHRH) and somatostatin. Adminis-
tration of GHRH by subcutaneous injection or continuous
infusion enhances endogenous GH secretion while preserving
the physiological pulsatile GH secretion pattern.13,14 There-
fore, stimulation of endogenous episodic GH release by
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GHRH administration may provide a more physiological
activation of the somatotropic hormone axis than the
direct subcutaneous injection of rhGH, which results in the
exposure of target tissues to a single large daily wave of
GH. Although human GHRH has been demonstrated to
stimulate statural growth in children, its clinical use was
largely abandoned because of its apparent slightly inferior
growth-promoting efficacy relative to rhGH.
AKL-0707 ([D-Ala2, D-Tyr10, D-Ala15, Lys22]hGHRH
(1–29)NH2) is a poly-substituted analog and super-agonist
of human GHRH. Relative to the native GHRH peptide,
AKL-0707 binds to the human GHRH receptor in vitro with
at least 900 times higher affinity and exhibits at least 25-fold
increased resistance to proteolysis in the human plasma.15
These properties make the compound a promising thera-
peutic alternative to rhGH. We carried out a placebo-
controlled randomized clinical trial to determine the efficacy
of AKL-0707 in stimulating endogenous GH secretion and
reversing uremic catabolism in adult patients with CKD-
associated protein-energy wasting.
RESULTS
Patients
A total of 28 subjects were randomized: 13 to AKL-0707 and
15 to placebo. Participant flow is presented in Figure 1.
Baseline characteristics were similar in both groups at the
time of screening (Table 1). A total of 26 subjects completed
the study as planned; 1 subject per group discontinued the
study for reasons other than adverse events (AEs). The first
subject was enrolled on 23 August 2005 and the last subject
completed the study on 23 March 2007.
GH/IGF-1
The mean area under the plasma GH concentration vs
time curve was similar in the two groups at baseline, and
increasedB9.5-fold during the initial 4 h after drug injection
(Po0.0001) and 5-fold in the 24-h concentration profile
(Po0.005) after AKL-0707 as compared with placebo
(Table 2, Figure 2). The difference in GH plasma concentra-
tions was brought about by commensurate increases in the
mass of GH released per hormone pulse and basal GH
secretion, without changes in GH pulse frequency, fraction of
pulsatile secretion, or regularity of pulses.
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Figure 1 | Trial design and patient flow. DXA, dual-energy X-ray absorptiometry; GHRH, growth-hormone-releasing hormone; pt, patient.
Table 1 | Baseline characteristics of the study subjects by
treatment randomization
AKL-0707
(n=13)
Placebo
(n=15)
Male (n) 6 9
Diabetic (n) 4 3
Hypertension (n) 12 14
Age, years 61.8±9.5 63.4±10.5
Body weight, kg 62.8±10.0 64.6±8.1
Body mass index, kg/m2 23.7±3.2 22.8±2.8
Fat-free mass (DXA), kg 43.8±10.9 46.4±8.3
Fat mass (DXA), kg 17.1±9.5 16.3±6.1
Total body bone mineral content, kg 2.2±0.7 2.4±0.5
Protein intake, g/kg per day 1.0±0.3 1.0±0.4
Energy intake, kcal/kg per day 26.9±7.2 27.1±7.9
nPNA, g/kg per day 1.2±0.6 1.0±0.5
Glomerular filtration rate,
ml/min per 1.73m2
20.4±5.8 17.9±8.0
Serum creatinine, mg/dl 3.1±0.7 3.8±1.3
Serum urea, g/dl 130±40 124±40
Serum albumin, g/l 39.6±6.7 40.4±5.3
Serum bicarbonate, mmol/l 23.0±5.4 22.0±4.0
Serum IGF-1, ng/ml 345±157 375±164
Serum IGFBP-1, ng/ml 75.0±39.1 75.8±25.3
Serum IGFBP-3, mg/ml 4.0±0.8 4.5±1.1
IGF-1/IGFBP-3 molar ratio 0.30±0.12 0.30±0.08
Abbreviations: DXA, dual-energy X-ray absorptiometry; IGF-1, insulin-like growth factor 1;
IGFBP-1, insulin-like growth factor binding protein-1; IGFBP-3, insulin-like growth factor
binding protein-3; nPNA, normalized protein equivalent of nitrogen appearance.
Data are mean±s.d., unless given otherwise.
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Plasma IGF-1 concentrations doubled within 3 weeks in
patients receiving AKL-0707 (Po0.01–0.001 vs controls from
day 7 to day 28) (Figure 3). Conversely, plasma IGF-binding
protein (IGFBP)-1 levels decreased by B30% (Po0.01 vs
controls at day 28). Plasma IGFBP-3 was stimulated slightly
in the AKL-0707 group (P¼ 0.13). The molar IGF-1/IGFBP-3
ratio increased from 0.28±0.12 to 0.49±0.09 in the AKL-
0707 group (Po0.0001), but remained unchanged in the
placebo group (0.30±0.08 to 0.34±0.11). Two weeks after
discontinuation of AKL-0707, IGF-1, and IGFBPs, plasma
concentration levels had returned to baseline (and placebo
control) levels.
Leucine kinetics
Results of leucine kinetics studies are provided in Table 3.
Leucine oxidation and flux, as well as calculated rates of
protein synthesis and breakdown were similar in the two
treatment groups at baseline and after 4 weeks of treatment,
irrespective of whether normalization was performed by body
weight or by fat-free mass (FFM).
Body mass and composition
In patients receiving AKL-0707, their body weight increased
within the 28-day treatment period by a mean of 1.2 kg,
compared with 0.1 kg with placebo-treated patients (mean
difference 0.95%, 95% confidence interval (95% CI): 0.2–1.8,
Po0.05) (Figure 4). Correspondingly, the mean body mass
index increased by 0.42 kg/m2 in the AKL-0707 group
compared with 0.03 kg/m2 after placebo (ratio of means
1.0, 95% CI: 1.00–1.03, Po0.05).
Body composition analysis performed by dual-energy
X-ray absorptiometry (DXA) and bioimpedance (BIA)
showed that the increase in body mass was the net effect of
reciprocal changes in FFM and fat mass (FM) (Figure 4).
On day 28, mean FFM had increased in subjects receiving
AKL-0707 according to both DXA (1.83 kg) and BIA (3.3 kg),
and had decreased in the placebo group (1.39 kg by DXA;
0.8 kg by BIA). Conversely, FM decreased in the AKL-0707
group (0.51 kg by DXA; 1.8 kg by BIA) and increased in
the placebo group (1.21 kg by DXA; 1.3 kg by BIA). Changes
in FFM and FM differed significantly between the treatment
Table 2 | Effects of AKL-0707 on 24-h growth hormone concentration/secretion profiles
AKL-0707
N=12
Placebo
N=14 Difference or ratio of means* 95% CI P-value
Area under the curve (mIU/ml min) at 4 h
Baseline 413 (366) 403 (385) Ratio
Day 28 5103 (5053) 525 (707) 9.49 (4.4; 20.3) 0.0001a
Area under the curve (mIU/ml min) at 24 h
Baseline 3771 (2140) 3389 (1666) Difference
Day 28 18,580 (13 363) 4146 (3528) 11,585 (4571; 18,598) 0.0032b
Mean pulse frequency (per 24 h)
Baseline 8.09 (2.81) 10.54 (3.72) Difference
Day 28 9.07 (3.49) 8.76 (3.19) 0.8 (2.2; 3.8) 0.577b
Inter-pulse regularity
Baseline 2.35 (0.63) 2.87 (2.29) Difference
Day 28 1.95 (0.30) 2.01 (0.66) 0.0 (0.5; 0.4) 0.877b
Mass per pulse (mU/l)
Baseline 11.3 (7.0) 8.9 (9.4) Difference
Day 28 43.9 (36.2) 10.8 (14.8) 26.5 (7.2; 45.8) 0.009b
Basal secretion rate (mU/l per 24 h)
Baseline 26.9 (19.8) 19.7 (18.3) Ratio
Day 28 118 (102) 34.3 (25.1) 2.53 (1.34; 4.79) 0.007a
Pulsatile secretion rate (mU/l per 24 h)
Baseline 98.2 (49.3) 70.1 (45.4) Ratio
Day 28 457 (526) 98.5 (102) 2.81 (1.15; 6.89) 0.026a
Total secretion rate (mU/l per 24 h)
Baseline 125 (64) 90 (45) Ratio
Day 28 574 (594) 133 (115) 2.72 (1.23; 5.99) 0.016a
% Pulsatile secretion rate
Baseline 79.0 (9.1) 75.2 (22.1) Difference
Day 28 71.3 (16.2) 70.2 (14.5) 0.4 (11.6; 10.8) 0.945b
Abbreviations: ANOVA, analysis of variance; ANCOVA, analysis of covariance; CI, confidence interval.
Treatment comparison with ANCOVA, assuming log-normal distribution. *Selection of method of choice was based on distribution of residuals.
Data are given as mean (s.d.).
aTreatment comparison with nonparametric ANCOVA.
bANOVA for repeated measures, assuming normal distribution.
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groups, irrespective of the methodology used (Po0.05–0.01,
Figure 4).
Bone mineral content by DXA increased by 38±41 g with
AKL-0707 as compared with no change with placebo
(adjusted mean difference 40 g, 95% CI: 10–70 g; Po0.05).
Subjective Global Assessment
Among patients rated as ‘mildly to moderately malnourished’
at baseline, six out of nine subjects in the AKL-0707
group, but none out of seven in the placebo group, appeared
‘well-nourished’ after 28 days of therapy (Po0.01 for
overall change) (Figure 5). The Subjective Global Assessment
(SGA) ratings remained unchanged in each patient at the
follow-up visit 2 weeks after discontinuation of therapy.
Biochemical parameters of nutrition
Serum urea levels decreased from 130±43 to 96±26mg/dl
in the AKL-0707 group (Po0.01) as compared with un-
changed levels in placebo-treated patients (124±40 to 137±
46mg/dl), resulting in an adjusted mean difference of 44
(95% CI: 62 to 25mg/dl) (Po0.0001). Correspondingly,
the normalized protein equivalent of nitrogen appearance
decreased from 1.16±0.56 to 0.79±0.29 g/kg per day in
the AKL-0707 group (Po0.01) and remained constant in
the placebo group (1.00±0.53 to 1.01±0.40 g/kg per day).
Serum urea levels returned to baseline 2 weeks after termi-
nation of treatment with AKL-0707. Serum albumin levels
did not change significantly in either group and did not
differ at day 28 (37.7±6.3 vs 39.0±8.3 g/l). In addition, no
significant effects were observed for serum pre-albumin,
transferrin, leptin, and adiponectin. Protein intake remained
unchanged, similar to AKL and placebo administration
(day 28: 1.0±0.4 vs 1.0±0.3 g/kg per day, NS), and so did
energy intake (25±8.7 vs 27±9 gkcal/kg per day, NS).
Biochemical parameters of metabolic control
Significant differences between the treatment groups were
also noted with respect to changes in fasting insulin and
glucose levels in nondiabetic subjects. Fasting insulin levels
increased from 9.7±3.4 to 12.4±4.3 mU/ml in the AKL-0707
group (Po0.05), resulting in a 2.1 (95% CI: 1.5–3.0;
Po0.0001) ratio of means relative to placebo. Fasting glucose
increased from 4.9±0.3 to 5.3±0.7mmol/l (ratio of means
1.1 (95% CI: 1.0–1.2; Po0.005)). There was no significant
effect of AKL-0707 on insulin resistance as assessed by
homeostatic model assessment index either in the non-
diabetic (2.9±1.0 vs 1.6±1.0) or in the total intention-
to-treat population (9.7±19.5 vs 3.9±7). In addition, no
effect on HbA1c levels was detected.
Mean cholesterol values decreased from 5.1±1.0 to
4.7±0.6mmol/l in subjects receiving AKL-0707 as compared
with no change in the placebo group (Po0.05 for treatment
effect).
Safety
The two groups were generally matched with respect to AEs
(Table 4). A total of 70 treatment-emergent AEs were reported
in 12 subjects randomized to AKL-0707, and 58 AEs in 14
subjects randomized to placebo. The most frequently reported
AEs were injection site bruising, followed by red blood cell
count decrease and injection site pain, blood glucose increase,
and hemoglobin decrease. Four serious AEs were reported in
three subjects, but they were considered not study drug related.
Three out of four serious AEs occurred in the placebo group.
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Figure 2 |Representative 24-h growth hormone concentration profiles at baseline (day 0/1, blue) and after 4 weeks of
treatment (day 28/29; red). Left panel shows a patient from the placebo group; right panel shows a patient from the AKL-0707 group.
The 24-h profiling was started at 0800 hours on day 0 and at 1230 hours on day 28. Injections were performed at 0800 and 1600 hours
on day 28/29 profiles. GH, growth hormone.
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DISCUSSION
In this placebo-controlled study, we demonstrated the rapid
and profound effects of a novel GHRH super-agonist on the
endocrine and nutritional status and body composition of
malnourished patients with advanced pre-dialysis CKD.
AKL-0707 treatment increased circulating GH concentra-
tions by almost fivefold. This response was brought about by
an amplification of the physiological pulsatile GH secretion
pattern, with proportionate increases in the mass of GH
secreted per pulse and basal secretion rate but no change in
the frequency or orderliness of GH pulses. Qualitatively
similar results have been achieved with native GHRH in the
elderly.13
The restoration of GH secretion to a juvenile level was
associated with a doubling of serum IGF-1, a marked
suppression of IGFBP-1, and a slight increase in IGFBP-3
concentrations in serum. This endocrine response to GH
serves to increase IGF-1 bioavailability at the tissue level.
Low free IGF-1 and high IGFBP-1 levels are characteristic of
GH insufficiency in CKD and have been linked to poor
statural growth in uremic children.5,16 Treatment with
rhGH at pharmacological doses increases circulating IGF-1
and IGFBP-3 and decreases IGFBP-1 in pediatric CKD and
adult hemodialysis patients.10,17 The endocrine effects of
AKL-0707 were readily reversible; serum IGF-1 and binding
protein concentrations reached baseline levels within 2 weeks
of discontinuation of the drug.
GHRH super-agonist treatment was remarkably efficacious
in improving the state of nutrition and general well-being
of patients. SGA is a widely used, reliable, and efficient
method of standardized nutritional assessment at bedside
in nephrology, surgery, and oncology.18 Within 4 weeks of
blinded AKL-0707 administration, six out of nine patients
who were rated mildly to moderately malnourished by SGA
at baseline became well-nourished, as compared with no
change in controls receiving placebo.
This considerable clinical benefit corresponded to marked
changes in body composition. An average weight gain of
1 kg was observed, which was the net effect of an increase in
FFM and a reduction in FM. FFM gains were noted in 11 of
12 patients completing the AKL-0707 treatment period,
averaged 1.8 kg according to DXA, and contrasted with
a continued loss of FFM in the placebo group. This protein
anabolic effect of 4-week GHRH analog treatment is
comparable with the dose-related 1.9–3.1 kg gain of FFM
observed by DXA after 6 months of rhGH therapy in a
recent placebo-controlled trial of adult patients on main-
tenance hemodialysis.11 The significant decreases in serum
urea concentrations by 26% and in urinary nitrogen
appearance by 32% at unchanged protein intake provide
biochemical confirmation of the protein anabolism induced
by AKL-0707.
At the same time, FM decreased significantly with AKL-
0707 as compared with an increase in controls. The reduc-
tion in adipose tissue mass most likely reflects augmented
GH release, as GH pulses directly promote lipolysis.19
Lipolytic effects have been commonly observed in patients
receiving rhGH for various indications including healthy
elderly subjects,20 with conflicting results in hemodialysis
patients.11,21 rhGH is an effective treatment for HIV-associ-
ated visceral fat accumulation (‘lipodystrophy’). Recent data
have suggested that GHRH analogs, possibly by augmenting
endogenous pulsatile GH secretion patterns, might be
particularly effective in reducing abdominal fat accumula-
tion.22,23 In this context, it is noteworthy that AKL-0707 also
decreased total plasma cholesterol levels as compared with
placebo-treated controls.
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Another notable finding by DXA was the small but signi-
ficant increase in total body mineral content in AKL-0707-
treated subjects as compared with those treated with
placebo. Although long-term (46 months) rhGH substitu-
tion tends to improve bone mineralization in adults with
GH deficiency,24 no effect or even a transient reduction in
lumbar spine mineralization was noted on dialysis in patients
receiving rhGH.12 GH functions on bone both by stimulating
local IGF-1 production and by direct GH receptor activation
on osteoblasts, osteoclasts, and osteocytes.25 The latter
mechanism may be susceptible to the temporal pattern of
GH exposure and be more effectively activated by GHRH
analog-induced augmented endogenous pulsatile GH secre-
tion as compared with the more tonic GH profile obtained
by subcutaneous rhGH injections.
In view of the clinically visible improvement in nutritional
status, markedly increased FFM, and substantial reduction in
serum urea and normalized protein equivalent of nitrogen
Table 3 | Results of leucine kinetic studies
AKL-0707
N=13
Placebo
N=15
Adjusted mean difference or
50% median point estimate 95% CI P-value
Leucine oxidation (mmol/kg h)
Baseline mean (s.d.) 7.7 (4.5) 9.8 (6.9)
Day 28 mean (s.d.) 10.2 (4.9) 9.4 (11.2)
Change from baseline to day 28 mean (s.d.) 2.4 (5.7) 0.8 (10.7) 1.1 (6.0; 8.2) 0.75
Leucine flux (mmol/kg h)
Baseline mean (s.d.) 101.5 (21.5) 94.0 (24.7)
Day 28 mean (s.d.) 103.1 (31.3) 92.4 (21.1)
Change from baseline to day 28 mean (s.d.) 1.2 (30.1) 3.2 (25.5) 7.5 (12.0; 27.0) 0.43
Protein synthesis (mmol/kg h)
Baseline mean (s.d.) 93.7 (20.4) 84.2 (26.2)
Day 28 mean (s.d.) 92.9 (29.7) 83.0 (22.3)
Change from baseline to day 28 mean (s.d.) 1.2 (30.8) 4.0 (24.9) 6.9 (10.9; 24.7) 0.43
Protein breakdown (mmol/kg h)
Baseline mean (s.d.) 97.5 (21.5) 90.0 (24.7)
Day 28 mean (s.d.) 99.0 (31.2) 88.4 (21.1)
Change from baseline to day 28 mean (s.d.) 1.2 (30.1) 3.2 (25.5) 7.5 (11.9; 27.0) 0.43
Abbreviations: ANCOVA, analysis of covariance; CI, confidence interval.
Statistical comparisons were made by ANCOVA assuming normal distribution
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appearance, there is little doubt that AKL-0707 caused a
consistent anabolic effect, which makes the apparently
lacking effect on protein synthesis, breakdown, or net protein
balance in leucine kinetics studies difficult to explain.
Previous experience with rhGH administration in patients
with end-stage renal disease showed an improved net protein
balance and increased protein synthesis in subjects with
increased baseline 13C-leucine oxidation indicative of cata-
bolism.7 However, in our patients 13C-leucine oxidation
rates at baseline were markedly lower than those previously
observed in CKD patients.26 It has been argued that in stable
chronic illnesses, whole-body protein turnover may be down-
regulated by an adaptive metabolic response to a lower steady
state. Furthermore, the normalized protein homeostasis in
our patients might be attributable to the careful correction of
metabolic acidosis, which was required before participation
in the study. It has been shown that correction of meta-
bolic acidosis mitigates whole-body protein degradation in
patients with CKD.27
In addition, the kinetic study was carried out in the fasting
state, a condition characterized by low endogenous insulin
and high cortisol release. The sensitivity to detect anabolic
effects of GHRH might have been higher in the postfeeding
state. In addition, regional kinetic studies, measuring turn-
over in leg or arm muscle, might be more sensitive than
studies of whole-body turnover. However, as regional kinetic
studies need to cannulate a set of major arteries and veins, we
opted against this more invasive approach because of safety
considerations. Finally, the apparent lack of stimulation of
net protein synthesis as assessed by leucine kinetics despite
the obvious net accretion of lean body mass in the AKL-0707
group might reflect differences in effect dynamics. In GH-
deficient adults, rhGH therapy suppressed leucine oxidation
at 2 weeks; while this early response was predictive of the
FFM increase and FM decrease at 12 weeks, leucine oxidation
had already returned to baseline levels and was not correlated
with the change in body composition observed at the
12-week time point.28
AKL-0707 was very well tolerated; the number and nature
of AEs observed were consistent with the underlying disease
without a pattern distinguishing the treatments from each
other. As hypertension due to fluid retention is a common
early side effect of rhGH treatment in CKD, it was reassuring
that blood pressure remained constant in AKL-0707 treated
patients.
In conclusion, in this proof-of-concept phase II study of
AKL-0707 GHRH super-agonist in malnourished patients
with CKD, we demonstrated that AKL-0707 is safe and
tolerable and improves nutritional status and body composi-
tion even within a short treatment period. In individual
patients with advanced CKD, reduced blood urea nitrogen
accumulation due to increased muscle protein accretion
might help to delay the need for renal replacement therapy.
Follow-up studies with longer treatment duration and
larger sample sizes will be required to determine whether
the gain of lean body mass and attenuation of uremia will
help stabilizing patient well-being in pre-dialysis CKD, and
positively affect the physical functional status in these often
frail patients. In addition, it remains to be seen whether the
stimulation of endogenous pulsatile GH secretion by GHRH
analogs will confer a clinical benefit over direct exogenous
administration of rhGH.
MATERIALS AND METHODS
Study participants
Men and women aged over 40 years with clinically stable CKD stage
4 or 5 (glomerular filtration rate 10–30ml/min per 1.73m2) and
malnutrition of any severity (defined by serum albumin p40 g/l,
body mass index p23mg/m2, or nonpurposeful 45% loss of body
weight in the previous 6 months), and who had given written
informed consent were eligible to participate in the study. Conco-
mitant erythropoietin therapy was allowed if dose was unchanged
for the previous 8 weeks. Exclusion criteria were severe fluid
overload, severe anemia, uncontrolled metabolic acidosis, rapidly
progressive renal failure, history of neoplasia, glucocorticoid
treatment within the previous 4 weeks, active systemic inflammatory
Table 4 | Adverse and serious adverse events reported during
the study period
Event
AKL-0707
(N=13)
Placebo
(N=15)
Number of patients (% of total patients; number of adverse events)
Adverse events
Pre-treatment 5 (38.5; 13) 7 (46.7; 14)
On treatment 12 (92.3; 70) 14 (93.3; 58)
Resulting in study discontinuation 0 0
Number of patients (% of total patients)
Any event
Injection site bruising 4 (30.8) 5 (33.3)
Injection site pain 3 (23.1) 3 (20.0)
Nausea/vomiting 2 (15.4) 3 (20)
Diarrhea 2 (15.4) 1 (6.7)
Upper respiratory tract infection 2 (15.4) 4
Urinary tract infection 2 (15.4) 1 (6.7)
Fever 1 (7.7) 1 (6.7)
Hypertension 2 (15.4) 3 (20.0)
Edema 2 (15.4) 2
Osteopenia/osteoporosis 1 2 (13.3)
Neutrophilia 0 1 (6.7)
Angina pectoris 0 1 (6.7)
Cardiac arrest 1 (7.7) 0
Cardiac failure 0 1 (6.7)
Chronic obstructive pulmonary
disease
1 (7.7) 0
Acidosis 0 1 (6.7)
Hypercalcemia 1 (7.7) 0
Hypercholesterolemia 0 1 (6.7)
Hypertriglyceridemia 0 1 (6.7)
Dry mouth 1 (7.7) 0
Serious adverse events
On treatment
Cardiac disorders 1 (7.7) 1 (6.7)
Unspecified surgical and
medical procedures
0 1 (6.7)
Off treatment
Hospitalization 0 1 (6.7)
Death
Post-treatment cardiac arrest 1 (7.7) 0
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or infectious disease, congestive heart failure, active liver disease or
clinically relevant abnormal laboratory results, hypothyroidism,
history of drug abuse, or treatment with centrally acting drugs.
Pregnant or lactating women were excluded.
The study was conducted at three sites in Poland in accordance
with the Declaration of Helsinki and Good Clinical Practice Guide-
lines. The protocol was approved by the central ethics committee
at the Silesian University of Medicine (Katowice, Poland).
Study design, blinding, randomization, and interventions
Patients were randomly assigned to receive two daily subcutaneous
injections of either 1mg of AKL-0707 or placebo for 28 days.
Randomization was carried out with random permuted blocks of
four subjects. Supplies were numbered serially so that randomiza-
tion was achieved by assigning the subject to the next available
number in the sequence. Patients, all study personnel, and those
assessing the outcome were blinded, and the allocation sequence was
concealed until data base closure and issuance of final statistical
report. Treatment compliance was 100% as the investigational drug
was administered by a nurse.
After the initial screening visit, approval of participation and
randomization, subjects attended the clinic for five study visits at
7-day intervals, plus for a follow-up assessment 14 days after the
last dose. The trial protocol and patient flow is summarized in
Figure 1. A physical and anthropometric examination, BIA, and
blood tests were conducted at every visit. On days 0 and 28/29,
subjects underwent a whole-body DXA scan, 24-h GH profiling,
leucine kinetics studies, urine tests, and SGA. DXA-derived FFM,
FM, and bone mineral content were recorded for the total body,
arms, legs, and trunk. AEs and concomitant medications were
collected throughout the study.
Study objectives, hypothesis, and outcome measures
The primary objective was to determine the effect of treatment on
protein turnover as assessed by 13C leucine kinetics. Secondary
objectives were to determine the effect of AKL-0707 on endogenous
time-integrated 24-h GH secretion, circulating IGF-1, FFM and FM,
biochemical parameters of nutritional, and metabolic state (serum
albumin, pre-albumin, transferrin, leptin, adiponectin, glycosylated
hemoglobin, fasting glucose, insulin, lipids), spontaneous nutrient
intake (3-day dietary protocols), and safety and tolerability as
assessed by AE collection, physical examination, vital signs, routine
laboratory safety screening, and monitoring for human anti-drug
antibodies. The working hypothesis was that AKL-0707 would break
resistance to endogenous GH and reverse muscle wasting by
decreasing irreversible protein degradation.
Subjective Global Assessment
Subjective Global Assessment was completed at baseline, on day 28
and again on day 42, and included a review of the medical
history (weight and weight change, dietary intake, gastrointestinal
symptoms, disease state, and subject’s functional status), a physical
examination for negative changes in body composition (loss of
subcutaneous fat or muscle wasting), and signs of edema or
ascites.29 After evaluation, the subject was classified as well
nourished, mild to moderately malnourished, or severely malnour-
ished by the physicians.
GH deconvolution analysis
Growth hormone concentration time series were analyzed using a
recently developed automated deconvolution method, which was
mathematically verified by direct statistical proof and empirically
validated using hypothalamo-pituitary sampling and simulated
pulsatile time series.30,31 Deconvolution parameters comprised basal
secretion (b0), two half-lives (a1, a2), secretory-burst mass (Z0,
Z1), random effects on burst mass (sA), procedural/measurement
error (se), and a three-parameter flexible g-secretory-burst
waveform (b1, b2, b3). Parameters (and units) included frequency
(number of bursts per total sampling period, lambda of
Weibull’s distribution), regularity of inter-pulse intervals (unitless
gamma of Weibull), fast and slow half-lives (min), basal and
pulsatile secretion rates (concentration units per session), mass
secreted per burst (concentration units), and waveform shape
(mode, or time delay to maximal secretion after objectively
estimated burst onset, min).
Leucine kinetics
Fasting leucine kinetics were measured on days 0 and 29 using a
primed-constant infusion technique during substrate and isotropic
steady state.32 The priming dose consisted of 4 mmol/kg of L-[1-13C]
leucine and 0.11mg/kg of NaH13CO3 administered at a sustained
infusion rate for 4 h (Cambridge Isotope Laboratories, Andover,
MA, USA). Venous blood and breath samples were collected before
isotope administration and at 180, 195, 210, 225, and 240min after
the start of infusion. 13C-leucine and 13C-ketoisocaproate enrich-
ment in the plasma were quantified by gas chromatography-mass
spectrometry. Plasma leucine was converted to the heptafluorobu-
tyrl,n-propyl-ester and analyzed by negative chemical ionization,
whereas ketoisocaproate was converted to the trimethylsilyl-
quinoxalinol derivative and analyzed by electron ionization. Breath
CO2 was quantified by isotope ratio mass spectrometry by
monitoring masses 44 and 45. All analyses and calculations were
performed by Metabolic Solutions (Nashua, NH, USA).
Blood testing
Blood sampling for GH secretion profile commenced on day 0
(baseline) by collecting samples at 20-min intervals for 20 h,
followed by 10-min intervals for 4 h. The first dose of investigational
product was administered after GH sampling. On day 28, samples
were collected pre-dose, at 10-min intervals for the first 4 h and at
20-min intervals thereafter for a further 20 h.
Total IGF-1, IGFBP-1, IGFBP-3, and insulin were measured
weekly by a central laboratory using commercial kits and human
anti-drug antibodies by LAB Research (Laval, QC, Canada). All
other blood and urine chemistry analyses were performed locally.
Statistical analysis and sample size
All hypothesis tests were conducted with a two-sided significance
level of a¼ 0.05. All CIs were 95%. Numerical data with one data
point after baseline were analyzed using ANCOVA (analysis
of covariance) with the baseline value as covariate and treatment
and site as factors. If the assumption of (log) normality was
questionable, nonparametric ANCOVA with the baseline value as
covariate was used instead. If there were several data points after
baseline, ANOVA (analysis of variance) for repeated measures was
the method of choice. The ANOVA model included baseline as
covariate, site, treatment, and visit and treatment by visit interaction
term as factors. The final analysis method was selected as part
of blind data review.
The study was designed to show the superiority of AKL-0707
to placebo on protein turnover as assessed by leucine oxidation
rate. In a previous study in GH-deficient adults treated with GH
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replacement, the s.d. of the leucine oxidation rate varied between
9 and 17 mmol/kg.33 At this level of variability, 13 subjects per group
are required to detect a difference in means of 15 mmol/kg (that is,
B1 s.d.) at a power of 80% and an error probability of 5%.
Anticipating an overall dropout rate ofB20%, a total of 32 subjects
were planned to be randomized.
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